MARAVAI LIFESCIENCES HOLDINGS, INC.

MARAVAI LIFESCIENCES HOLDINGS, INC. Annual Report: A Comprehensive Review for Investors

Maravai LifeSciences navigated a dynamic market this past year, marked by strategic shifts and operational adjustments. For the fiscal year ending December 31, 2024, the company reported total revenue of $385 million, a decrease from $450 million in the prior year. This decline primarily stemmed from a return to normal demand for certain products after the pandemic surge. Despite this, Maravai actively repositioned itself for future growth through targeted acquisitions and a significant restructuring initiative.

Business Overview

Maravai operates through two core segments: TriLink BioTechnologies (TriLink), which produces nucleic acids, and Cygnus Technologies (Cygnus), which specializes in biologics safety testing.

• TriLink generated $260 million in revenue, down from $320 million in 2023, due to reduced demand for mRNA vaccine components.
• Cygnus delivered $125 million in revenue, a slight decrease from $130 million in 2023, demonstrating resilience in its core biologics testing services.

Geographically, North America led sales, contributing 60% of total revenue. Asia Pacific accounted for 20%, Europe (EMEA) 15%, and Latin & Central America 5%.

Financial Performance

The company's financial performance reflects the challenging revenue environment and the costs associated with its strategic realignment:

• Revenue: $385 million (down from $450 million in 2023).
• Gross Profit: $220 million, for a gross margin of 57%.
• Operating Expenses: Totaled $205 million, including:
  • Selling, General, and Administrative (SG&A): $120 million.
  • Research and Development (R&D): $50 million, showing continued investment in innovation.
  • Restructuring Charges: $35 million related to the A2025 Corporate Realignment Plan.
• Net Income: $10 million, significantly lower due to the revenue decline and restructuring costs, compared to $80 million in 2023.
• Diluted Earnings Per Share (EPS): $0.08.
• Cash Flow from Operations: $75 million, indicating healthy operational cash generation despite lower net income.

Management Discussion

Key Developments and Strategic Initiatives

1. Strategic Acquisitions: Maravai expanded its capabilities with two significant acquisitions, completed shortly after the 2024 fiscal year-end:

   • Molecular Assemblies Inc. (acquired January 2025): A leader in enzymatic DNA synthesis, this acquisition will enhance TriLink's nucleic acid offerings, expand its intellectual property, and position Maravai in the rapidly evolving synthetic biology market.
   • Officinae Bio (acquired February 2025): This acquisition strengthens Maravai's presence in advanced biologics development and manufacturing, especially in gene therapy applications. It complements Cygnus's biologics safety testing services. These moves are crucial for diversifying revenue and entering high-growth areas.

2. A2025 Corporate Realignment Plan: Initiated in November 2023 and largely implemented throughout 2024, this plan aimed to streamline operations, cut costs, and focus resources on strategic priorities. The $35 million in restructuring charges included $15 million for employee severance, $10 million for asset write-offs, and $10 million for professional fees. Though it impacted short-term profits, this plan aims to improve long-term efficiency and profitability.

3. Customer Concentration: Maravai faces a notable challenge: its reliance on Nacalai USA Inc. This single customer generated 18% of Maravai's total 2024 revenue and represented 25% of its year-end accounts receivable. This concentration poses a significant risk; any reduction in Nacalai USA Inc.'s orders or financial difficulties could significantly impact Maravai's financial performance.

Financial Health

Maravai maintains a solid financial position:

• Cash and Cash Equivalents: $150 million at year-end 2024.
• Debt: The company entered into a New Credit Agreement in mid-2024, including $300 million in secured term loans and a $75 million revolving credit facility. By December 31, 2024, $280 million of the term loans were outstanding, leaving $20 million available from the revolving credit facility. This structure provides ample liquidity for ongoing operations and strategic investments.
• Debt Maturity: The term loans mature in 2029, ensuring a stable long-term capital structure.

Risk Factors

• Customer Concentration: The substantial reliance on Nacalai USA Inc. (18% of revenue) is a primary risk, making customer diversification critical.
• Integration of Acquisitions: Successfully integrating Molecular Assemblies Inc. and Officinae Bio – their technologies, operations, and cultures – will be crucial for realizing anticipated strategic benefits.
• Restructuring Execution: While the A2025 plan targets efficiency, unforeseen challenges or higher costs could impact future profitability.
• Competitive Landscape: The life sciences tools and services market is highly competitive, demanding continuous innovation and effective commercialization.
• Regulatory Changes: Evolving regulations in drug development and manufacturing could affect demand for Maravai's products and services.

Competitive Position

Maravai operates in specialized niches within the broader life sciences market. Its competitive advantage comes from proprietary technologies in nucleic acid synthesis (TriLink) and established expertise in biologics safety testing (Cygnus). Maravai competes on product quality, scientific expertise, and customer service, serving diverse pharmaceutical, biotechnology, and academic customers. Recent acquisitions aim to strengthen its competitive edge in emerging areas like synthetic biology and gene therapy.

Future Outlook

Maravai's strategy is clear: streamline existing operations and strategically expand into high-growth areas. The A2025 Corporate Realignment Plan should yield $25-30 million in annualized cost savings starting in 2025, boosting operating margins. The acquisitions of Molecular Assemblies Inc. and Officinae Bio are key to diversifying its product portfolio and reducing reliance on specific market segments, especially post-pandemic mRNA demand.

For fiscal year 2025, Maravai anticipates revenue stabilization and a return to modest growth, projecting revenues between $395 million and $420 million. New acquisitions and a more efficient operational structure will drive this growth. The company remains committed to innovation and leveraging its core strengths to drive long-term shareholder value.

What this means for you: Maravai is navigating a post-pandemic market shift by cutting costs and making strategic acquisitions to diversify its revenue streams and enter new growth areas. While 2024 saw a dip in revenue and net income due to these changes, the company projects a return to growth in 2025. Keep an eye on how well they integrate their new acquisitions and manage their customer concentration risk, as these will be key to their long-term success.